Universal CAR-T Cell Therapy for NHL

This is a single-center, single-arm, open-label clinical study, and the sample size is set to 3-6 subjects.

Trial Details

NCT ID
NCT07248163
Phase
NA
Sponsor
Bioray Laboratories
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • BRL-301
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Willing to participate in this clinical study and sign an informed consent form;
  • Age ≥ 18 years old;
  • Estimated survival time ≥ 3 months;
  • At least one measurable lesion;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →